ORKA vs LNTH stock comparison
Oruka Therapeutics vs. Lantheus · data as of November 13, 2026
Oruka Therapeutics (ORKA) has a market value of about $7.1B, Lantheus (LNTH) about $6.6B.
On our five checks Lantheus scores higher: 2.6 out of 5 (average) against 0.4 (weak).
By area, the stronger company is Lantheus on value; Lantheus on future growth; Lantheus on track record; Lantheus on financial health; Lantheus on shareholder returns.
Oruka Therapeutics leads on 1 of the compared lines and Lantheus on 10.
Side by side
| ORKA | LNTH | |
|---|---|---|
| Size and price | ||
| Market cap | $7.1B | $6.6B |
| Share price | $105.35 | $101.59 |
| Score | ||
| Overall score (of 5) | 0.4 | 2.6 |
| Value | 0 | 1 |
| Future growth | 0 | 3 |
| Track record | 0 | 2 |
| Financial health | 2 | 5 |
| Shareholder returns | 0 | 2 |
| Valuation | ||
| P/E (TTM) | — | 25.1 |
| Forward P/E | — | 16.0 |
| Price / free cash flow | — | 16.9 |
| Price / sales | — | 4.3 |
| EV / EBITDA | — | 17.2 |
| PEG | — | — |
| DCF value vs. price | — | −35% |
| Business | ||
| Revenue | — | $1.6B |
| Net income | -$105M | $270M |
| Free cash flow | -$88M | $393M |
| Net margin | — | 17.3% |
| Gross margin (5-yr avg.) | — | 57.3% |
| ROIC (5-yr avg.) | -22.8% | 9.4% |
| Growth | ||
| Revenue growth (1 yr) | — | 0.5% |
| Revenue growth (5 yrs, per year) | — | 35.4% |
| EPS growth (5 yrs, per year) | — | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | — | $59M |
| Dividend yield | None | None |
| Shareholder yield | 0.0% | 4.5% |
| Analysts | ||
| Upside to average target | +48% | +4% |
| Consensus rating | Strong buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: ORKA FY2025, LNTH TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Oruka Therapeutics or Lantheus?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Lantheus scores 2.6 out of 5 and Oruka Therapeutics 0.4; the table shows where each one is stronger.
Full Oruka Therapeutics analysis → Full Lantheus analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.